Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 76343, held by Cipla Ltd. Topiramate.
As of Nov 15, 2026, ANDA 76343 (Topiramate), held by Cipla Ltd, was first approved by FDA on Mar 27, 2009, with 15 approved supplements and 0 published complete response letters.
Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved | None posted |
| Topiramate25MG · tablet;oral | Topiramate | Rx |
| Topiramate50MG · tablet;oral | Topiramate | Rx |
| Topiramate100MG · tablet;oral | Topiramate | Rx |
| Topiramate200MG · tablet;oral | Topiramate | Rx |
| Sep 8, 2023 | Supplement 29Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 26Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 27Labeling · Standard review | Approved | None posted |
| Nov 19, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 27, 2010 | Supplement 3Labeling | Approved | None posted |
| Sep 30, 2009 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters